Biotech mergers and acquisitions are gaining momentum as Big Pharma seeks to offset upcoming patent losses. Among potential targets, Legend Biotech stands out for its revenue-generating CAR-T therapy Carvykti, co-developed with Johnson & Johnson, showing strong sales growth and nearing profitability. Its share price is undervalued, making it an attractive acquisition candidate with minimal integration challenges. Revolution Medicines and Structure Therapeutics also present opportunities but face higher prices or clinical risks. Legend Biotech is the most actionable target as biotech dealmaking accelerates.
BOTOX Cosmetic, under Allergan Aesthetics and AbbVie, announced 250 women entrepreneurs chosen for The Confidence Collective program, offering skill-building, mentorship, and networking. From this group, 20 participants will receive $20,000 grants to...
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
Canada has approved Boey®, the first rapid-onset and short-duration botulinum neurotoxin serotype E, for temporarily improving moderate to severe glabellar (frown) lines. Developed by Allergan Aesthetics, Boey® offers results visible as early as eigh...
Following AbbVie's pending acquisition of Apogee Therapeutics, big pharma is actively seeking clinical-stage biotech firms with late-stage data and strategic fit in immunology, obesity, or oncology. Among Nasdaq-listed biotechs, Syndax Pharmaceutical...
The European Union has approved MAVIRET (glecaprevir/pibrentasvir) for treating acute hepatitis C virus (HCV) infection in adults and children aged 3 and older. This is the only treatment in the EU approved for both acute and chronic HCV, enabling ea...
